169 related articles for article (PubMed ID: 34295662)
41. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
[TBL] [Abstract][Full Text] [Related]
42. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.
Duan J; Cui L; Zhao X; Bai H; Cai S; Wang G; Zhao Z; Zhao J; Chen S; Song J; Qi C; Wang Q; Huang M; Zhang Y; Huang D; Bai Y; Sun F; Lee JJ; Wang Z; Wang J
JAMA Oncol; 2020 Mar; 6(3):375-384. PubMed ID: 31876895
[TBL] [Abstract][Full Text] [Related]
43. Effect of region on the Outcome of Patients Receiving PD-1/PD-L1 Inhibitors for Advanced Cancer.
Wang Z; Zhang B; Zhang C; Ren S; Wang W; Wang Y; Jiang T; Wei H; Li Y; Wu Q; Chen J
Int Immunopharmacol; 2019 Sep; 74():105709. PubMed ID: 31276976
[TBL] [Abstract][Full Text] [Related]
44. PD-(L)1 Inhibitors in Combination with Chemotherapy as First-Line Treatment for Non-Small-Cell Lung Cancer: A Pairwise Meta-Analysis.
García-González J; Ruiz-Bañobre J; Afonso-Afonso FJ; Amenedo-Gancedo M; Areses-Manrique MDC; Campos-Balea B; Casal-Rubio J; Fernández-Núñez N; Fírvida Pérez JL; Lázaro-Quintela M; Pérez Parente D; Crama L; Ruiz-Gracia P; Santomé-Couto L; León-Mateos L
J Clin Med; 2020 Jul; 9(7):. PubMed ID: 32635291
[TBL] [Abstract][Full Text] [Related]
45. Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials.
Khan M; Lin J; Liao G; Tian Y; Liang Y; Li R; Liu M; Yuan Y
Medicine (Baltimore); 2018 Aug; 97(33):e11936. PubMed ID: 30113497
[TBL] [Abstract][Full Text] [Related]
46. Efficacy and safety of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC): a systematic literature review.
Wagner G; Stollenwerk HK; Klerings I; Pecherstorfer M; Gartlehner G; Singer J
Oncoimmunology; 2020 Jun; 9(1):1774314. PubMed ID: 32923134
[TBL] [Abstract][Full Text] [Related]
47. Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma-an exploration of surrogate endpoint.
Zhang Z; Xie C; Gao T; Yang Y; Yang Y; Zhao L
BMC Cancer; 2023 Feb; 23(1):145. PubMed ID: 36765311
[TBL] [Abstract][Full Text] [Related]
48. Antibiotic treatment and survival in non-small cell lung cancer patients receiving immunotherapy: a systematic review and meta-analysis.
Abdelhamid A; Tuminello S; Ivic-Pavlicic T; Flores R; Taioli E
Transl Lung Cancer Res; 2023 Dec; 12(12):2427-2439. PubMed ID: 38205205
[TBL] [Abstract][Full Text] [Related]
49. A meta-analysis on immune checkpoint inhibitor efficacy for advanced non-small cell lung cancer between East Asians versus non-East Asians.
Peng S; Ying AF; Tai BC; Soo RA
Transl Lung Cancer Res; 2020 Aug; 9(4):1124-1137. PubMed ID: 32953491
[TBL] [Abstract][Full Text] [Related]
50. FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodies.
Marur S; Singh H; Mishra-Kalyani P; Larkins E; Keegan P; Sridhara R; Blumenthal GM; Pazdur R
Semin Oncol; 2018 Aug; 45(4):220-225. PubMed ID: 30391014
[TBL] [Abstract][Full Text] [Related]
51. Anti-PD-1/PD-L1 antibody therapy for pretreated advanced nonsmall-cell lung cancer: A meta-analysis of randomized clinical trials.
Zhou GW; Xiong Y; Chen S; Xia F; Li Q; Hu J
Medicine (Baltimore); 2016 Aug; 95(35):e4611. PubMed ID: 27583876
[TBL] [Abstract][Full Text] [Related]
52. Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis.
Mori K; Pradere B; Quhal F; Katayama S; Mostafaei H; Laukhtina E; Schuettfort VM; D'Andrea D; Egawa S; Bensalah K; Schmidinger M; Powles T; Shariat SF
Cancer Treat Rev; 2021 Sep; 99():102242. PubMed ID: 34153830
[TBL] [Abstract][Full Text] [Related]
53. Indirect comparison between immunotherapy alone and immunotherapy plus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a systematic review.
Li L; Xu F; Chen Y; Ren X; Liu Y; Chen Y; Xia S
BMJ Open; 2020 Nov; 10(11):e034010. PubMed ID: 33444168
[TBL] [Abstract][Full Text] [Related]
54. Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-analysis.
Zhou T; Zhang Z; Luo F; Zhao Y; Hou X; Liu T; Wang K; Zhao H; Huang Y; Zhang L
JAMA Netw Open; 2020 Oct; 3(10):e2015748. PubMed ID: 33074323
[TBL] [Abstract][Full Text] [Related]
55. Is there any place for PD-1/CTLA-4 inhibitors combination in the first-line treatment of advanced NSCLC?-a trial-level meta-analysis in PD-L1 selected subgroups.
Passiglia F; Galvano A; Gristina V; Barraco N; Castiglia M; Perez A; La Mantia M; Russo A; Bazan V
Transl Lung Cancer Res; 2021 Jul; 10(7):3106-3119. PubMed ID: 34430351
[TBL] [Abstract][Full Text] [Related]
56. [The efficacy and prognostic factors of immunotherapy in advanced non-small cell lung cancer patients with different driver gene mutations].
Ma SX; Ma N; Han J; He Z; Wang L; Wang Q
Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(13):922-929. PubMed ID: 35385963
[No Abstract] [Full Text] [Related]
57. PD-L1 expression and EGFR status in advanced non-small-cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis.
Li J; Gu J
Future Oncol; 2019 May; 15(14):1667-1678. PubMed ID: 31041879
[No Abstract] [Full Text] [Related]
58. The benefits and risks of CTLA4 inhibitor plus PD1/PDL1 inhibitor in stage IIIB/IV non-small cell lung cancer: A systematic analysis and meta-analysis based on randomized controlled trials.
Liu Q; Fang Z; Liu M; Xu R; Yi F; Wei Y; Zeng L; Zhang W
J Clin Pharm Ther; 2021 Dec; 46(6):1519-1530. PubMed ID: 34101874
[TBL] [Abstract][Full Text] [Related]
59. Sex-based differences in response to anti-PD-1 or PD-L1 treatment in patients with non-small-cell lung cancer expressing high PD-L1 levels. A systematic review and meta-analysis of randomized clinical trials.
Conforti F; Pala L; Pagan E; Corti C; Bagnardi V; Queirolo P; Catania C; De Pas T; Giaccone G
ESMO Open; 2021 Oct; 6(5):100251. PubMed ID: 34455288
[TBL] [Abstract][Full Text] [Related]
60. A Network Meta-Analysis of Cancer Immunotherapies
Herbst R; Jassem J; Abogunrin S; James D; McCool R; Belleli R; Giaccone G; De Marinis F
Front Oncol; 2021; 11():676732. PubMed ID: 34307144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
